Arbutus Biopharma's worrying high P/S ratio is underscored b...
Arbutus Biopharma's worrying high P/S ratio is underscored by its falling revenue. Investors could pay a steep premium as these declines might significantly affect the stock's value.
What Arbutus Biopharma Corporation's (NASDAQ:ABUS) 26% Share Price Gain Is Not Telling You
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3204Followers
0Following
7975Visitors
Follow